NovoCure Limited (NVCR) Stock Forecast
NVCR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 7 analysts
- Price target
- $26.86 average of analyst targets
- Upside to target
- +90.9% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $-0.21
- 52-week range
- $10.03 – $19.99
NVCR analyst ratings
7 analystsNumber of analysts at each rating.
NVCR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NVCR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.31 | −$0.14 | −$0.33 | +28.8% | 7 |
| Current fiscal year (2026) | −$1.24 | −$1.37 | −$1.05 | −$1.22 | −1.2% | 7 |
| Next fiscal year (2027) | −$0.81 | −$1.26 | −$0.22 | −$1.24 | +34.7% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NVCR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $182.2M | $179.7M | $187.0M | +9.0% | 7 |
| Current fiscal year (2026) | $726.1M | $718.3M | $737.1M | +10.8% | 7 |
| Next fiscal year (2027) | $804.8M | $776.2M | $856.0M | +10.8% | 7 |
NVCR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NVCR revenue: reported and forecast
NVCR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.33 | −$0.24 | −$0.24 | −$0.24 | −$0.23 | −28.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.59 | −$1.25 | −$1.25 | −$1.25 | −$1.24 | −22.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.19 | −$0.82 | −$0.82 | −$0.82 | −$0.81 | −32.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NVCR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NVCR beat in 10 of 12.
What analysts expect from NVCR
7 analysts cover NovoCure; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $26.86, 90.9% above the latest close of $14.07. Analysts expect earnings of −$1.24 per share for 2026, −1.2% from a year earlier. For 2027 the average estimate is −$0.81 per share on revenue of $804.8 million. NovoCure beat the EPS estimate in 10 of the last 12 quarters.
Related: NVCR income statement, NVCR key metrics, NVCR chart. See the NVCR stock overview for the latest quote and news.
NVCR forecast FAQ
What is NovoCure's price target?
The average analyst price target for NovoCure is $26.86, 90.9% above the latest close of $14.07.
Is NovoCure a buy, hold or sell?
Of 7 analysts covering NovoCure, 3 rate it a strong buy, 1 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NovoCure's EPS forecast?
Analysts forecast −$1.24 per share for 2026 (range −$1.37 to −$1.05); for 2027 the estimate is −$0.81.
What is NovoCure's revenue forecast?
The average revenue estimate for 2026 is $726.1 million, growth of 10.8%; for 2027 it is $804.8 million.
When does NovoCure report earnings?
NovoCure is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $-0.21.
Does NovoCure usually beat earnings estimates?
NovoCure reported EPS at or above the analyst estimate in 10 of the last 12 quarters.